Monday, February 10, 2025
spot_imgspot_img

Top 5 This Week

spot_imgspot_img

Related Posts

New drug undergoing clinical trial in North Texas could potentially increase dogs’ lifespans


A groundbreaking clinical trial is currently underway in North Texas to determine whether a new drug developed by biotech company Loyal can extend the lifespan of older dogs. The STAY study, which aims to enroll 1,000 senior dogs across the country, is the first of its kind to be up for FDA approval. Dogs participating in the trial will take one pill per day, with all costs covered by the company. The four-year study is the final step needed for FDA approval.

One of the participating clinics in the trial is Advanced Care Veterinary Services in Carrollton, where 13-year-old chocolate lab Bella is undergoing treatment. The medication aims to interrupt metabolic dysfunction in aging dogs, allowing their metabolism to work better and longer. While enrolled dogs will receive either the actual medication or a placebo in a double-blind study, the goal is to prolong a dog’s healthy lifespan.

Enrollment criteria for the trial include being 10 years or older, weighing 14 pounds or more, and living near a participating vet clinic. Dogs with certain medical conditions, such as cancer, severe heart issues, and diabetes, will be excluded from the trial.

For dog owner Kenny Coomes, participating in the trial is a chance to possibly extend Bella’s life and enhance her quality of life. Regardless of whether Bella is benefiting from the medication or the placebo effect, Coomes remains hopeful that she will have more years with his beloved companion. More information on Loyal’s clinical trial can be found on their website.

Source
Photo credit www.fox4news.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Articles